An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib

← catalyst calendar

NCT02955940 · readout in 406 d

Sponsored by Incyte Corporation (industry) · INCY — their whole pipeline →.

Phase

Phase 2

Status

Active, not recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

10actual

Sites

Countries

Poland, United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2016-11-30

actual

When the study began enrolling

Primary completion

2027-09-30

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2027-09-30

estimated

The whole study's end, after follow-up

First posted

2016-11-04

estimated

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-17

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Pancreatic Cancer
Colorectal Cancer (CRC)
Breast Cancer
Lung Cancer

Interventions

Drug: Ruxolitinib — also filed as INCB018424, Jakafi®
Drug: Capecitabine — also filed as Xeloda®
Drug: Regorafenib — also filed as Stivarga®

Primary outcome

what the primary-completion date above is the date OF

Frequency and types of adverse events and serious adverse events

measured Maximum duration of every 2 months (maximum duration of 1 month for subjects receiving regorafenib) from enrollment through 30-37 days after end of treatment up to 24 months.

Permalink · INCY's whole pipeline · Catalyst calendar · Every registered study · What changed